Novartis AG
SIX:NOVN
Relative Value
The Relative Value of one
NOVN
stock under the Base Case scenario is
hidden
CHF.
Compared to the current market price of 125.02 CHF,
Novartis AG
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
NOVN Competitors Multiples
Novartis AG Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Novartis AG
SIX:NOVN
|
238.2B CHF | 5.5 | 22.1 | 13.7 | 17.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.7B USD | 14.6 | 46.2 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.1B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
262.5B CHF | 4.3 | 20.4 | 12 | 13.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP | 5.1 | 29.3 | 16.2 | 22.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 17.3 | 7.3 | 9 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
83.2B GBP | 2.5 | 14.5 | 7.4 | 10.5 |